Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ARV-471 + everolimus
- Development stage
- Phase 1
- Lead developer
- Arvinas
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
ARV-471 (vepdegestrant) is an investigational, orally bioavailable PROTAC (proteolysis-targeting chimera) small molecule designed to selectively degrade the estrogen receptor (ER) in ER-positive breast cancer. It works by binding both the estrogen receptor and the E3 ligase cereblon, leading to ubiquitination and proteasomal degradation of ER. Everolimus is an mTOR inhibitor already approved for use in various cancers, including breast cancer. The combination of ARV-471 and everolimus is being studied for its potential synergistic effect in treating advanced or metastatic ER-positive, HER2-negative breast cancer. This combination aims to improve outcomes by targeting both hormone signaling and cell growth pathways[1][3][4][5].
- Other names
- vepdegestrant + everolimus
02
Targets
CRL4-CRBN (Cereblon-based E3 ubiquitin ligase complex)ESR1 (ERα)Mechanistic target of rapamycin complex 1
Beyond the preview
Go deeper on ARV-471 + everolimus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ARV-471 + everolimus.